Rehospitalization Risk of Receptor-Affinity Profile in Antipsychotic Drug Treatment: A Propensity Score Matching Analysis Using a Japanese Employment-Based Health Insurance Database

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2020 Dec 10

PMID 33299315

Authors

Yoshiteru Takekita

Sachie Inoue

Kenji Baba

Tadashi Nosaka

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to examine whether there is a difference in the risk of rehospitalization when antipsychotics are classified into two groups treated using drugs with a higher or lower affinity to H1 or α1 receptors than to D2 receptors (histamine H1 receptors, adrenaline α1 receptors [HA] high- and HA low-affinity drug group, respectively) based on affinity to receptors related to sedation using a nationwide insurance claims database in Japan.

Patients And Methods: We identified eligible patients by the following two criteria: (i) hospitalization due to schizophrenia (International Classification of Disease [ICD]-10 code: F20 or F25) in psychiatric wards between January 1st, 2005 and August 31st, 2017, and (ii) administration of HA high- or HA low-affinity drugs in the next month after discharge from the earliest hospitalization due to schizophrenia (index month). The primary endpoint was rehospitalization due to schizophrenia. The secondary endpoints were (i) involuntary rehospitalization, (ii) concomitant use of anxiolytics/hypnotics, mood stabilizers, and antiparkinsonian drugs, (iii) all-cause death, and (iv) medication discontinuation. Propensity score (PS) matching analysis was applied, and the hazard ratio (HR) of the event rate in the HA high-affinity drug group relative to the HA low-affinity drug group was calculated using Cox's proportional hazards model.

Results: Two thousand nine hundred and forty patients were identified as eligible patients. Among PS-matched patients (819 in each group), the HR in the HA high-affinity drug group compared with the HA low-affinity drug group was 1.018 (0.822-1.260, P = 0.870). Other outcomes did not differ significantly between the two groups.

Conclusion: No significant difference was observed in the rehospitalization risk due to schizophrenia associated with HA high-affinity antipsychotic drugs. Although this study was a retrospective PS-matched cohort study, the possibility of masking of the rehospitalization risk cannot be excluded because more than 80% of the patients were administered an anxiolytic/hypnotic at the time of admission.

References

Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali A . Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013; 145(1-3):101-9. DOI: 10.1016/j.schres.2013.01.009. View

Hatano M, Kamei H, Kato A, Takeuchi I, Hanya M, Uno J . Assessment of the Latent Adverse Events of Antipsychotic Treatment Using a Subjective Questionnaire in Japanese Patients with Schizophrenia. Clin Psychopharmacol Neurosci. 2017; 15(2):132-137. PMC: 5426495. DOI: 10.9758/cpn.2017.15.2.132. View

MacEwan J, Kamat S, Duffy R, Seabury S, Chou J, Legacy S . Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics. Psychiatr Serv. 2016; 67(11):1183-1188. DOI: 10.1176/appi.ps.201500455. View

Velligan D, Sajatovic M, Hatch A, Kramata P, Docherty J . Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017; 11:449-468. PMC: 5344423. DOI: 10.2147/PPA.S124658. View

Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F . An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf. 2016; 15(10):1329-47. DOI: 10.1080/14740338.2016.1201475. View

Afonso P, Brissos S, Canas F, Bobes J, Bernardo-Fernandez I . Treatment adherence and quality of sleep in schizophrenia outpatients. Int J Psychiatry Clin Pract. 2013; 18(1):70-6. DOI: 10.3109/13651501.2013.845219. View

Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane J . Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013; 147(1):95-102. DOI: 10.1016/j.schres.2013.03.013. View

Pilon D, Amos T, Germain G, Lafeuille M, Lefebvre P, Benson C . Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program. Curr Med Res Opin. 2017; 33(4):713-721. DOI: 10.1080/03007995.2016.1277989. View

Orsolini L, de Berardis D, Volpe U . Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Opin Drug Saf. 2020; 19(8):981-998. DOI: 10.1080/14740338.2020.1795126. View

10.

Steyerberg E, Vickers A, Cook N, Gerds T, Gonen M, Obuchowski N . Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2009; 21(1):128-38. PMC: 3575184. DOI: 10.1097/EDE.0b013e3181c30fb2. View

11.

Lafeuille M, Grittner A, Fortier J, Muser E, Fasteneau J, Duh M . Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. Am J Health Syst Pharm. 2015; 72(5):378-89. DOI: 10.2146/ajhp140219. View

12.

Weiden P, Kozma C, Grogg A, Locklear J . Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004; 55(8):886-91. DOI: 10.1176/appi.ps.55.8.886. View

13.

Shimada T, Nishi A, Yoshida T, Tanaka S, Kobayashi M . Factors Influencing Rehospitalisation of Patients with Schizophrenia in Japan: A 1-year Longitudinal Study. Hong Kong J Occup Ther. 2018; 28(1):7-14. PMC: 6091990. DOI: 10.1016/j.hkjot.2016.10.002. View

14.

Gray J, Roth B . The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007; 12(10):904-22. DOI: 10.1038/sj.mp.4002062. View

15.

Limosin F, Belhadi D, Comet D, Pacou M, Bouju S, Van Impe K . Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients: Results From a Multicenter Retrospective Cohort Study in France. J Clin Psychopharmacol. 2017; 38(1):19-26. PMC: 5737453. DOI: 10.1097/JCP.0000000000000827. View

16.

Correll C . From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010; 25 Suppl 2:S12-21. DOI: 10.1016/S0924-9338(10)71701-6. View

17.

Lafeuille M, Laliberte-Auger F, Lefebvre P, Frois C, Fastenau J, Duh M . Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry. 2013; 13:221. PMC: 3847215. DOI: 10.1186/1471-244X-13-221. View

18.

Stroup T, Gerhard T, Crystal S, Huang C, Olfson M . Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. Am J Psychiatry. 2015; 173(2):166-73. DOI: 10.1176/appi.ajp.2015.15030332. View

19.

Greene M, Yan T, Chang E, Hartry A, Touya M, Broder M . Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2017; 21(2):127-134. DOI: 10.1080/13696998.2017.1379412. View

20.

de Berardis D, Rapini G, Olivieri L, Di Nicola D, Tomasetti C, Valchera A . Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf. 2018; 9(5):237-256. PMC: 5956953. DOI: 10.1177/2042098618756261. View